CG
ALLO icon

Cutler Group’s Allogene Therapeutics ALLO Stock Holding History

Cutler Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,360
Closed -$4K – 3559
2023
Q3 		$4K Hold
1,360
– – ﹤0.01% 2913
2023
Q2 		$6K Hold
1,360
– – ﹤0.01% 2499
2023
Q1 		$6K Hold
1,360
– – ﹤0.01% 2594
2022
Q4 		$8K Hold
1,360
– – ﹤0.01% 2814
2022
Q3 		$14K Sell
1,360
-1,740
-56% -$23.6K ﹤0.01% 2852
2022
Q2 		$35K Sell
3,100
-3,142
-50% -$27.9K ﹤0.01% 2212
2022
Q1 		$56K Buy
6,242
+1,300
+26% +$13.5K ﹤0.01% 2147
2021
Q4 		$73K Buy
4,942
+3,242
+191% +$57.2K ﹤0.01% 2095
2021
Q3 		$43K Sell
1,700
-200
-11% -$4.75K ﹤0.01% 2633
2021
Q2 		$49K Buy
1,900
+1,500
+375% +$42.8K ﹤0.01% 2497
2021
Q1 		$14K Buy
+400
New +$13.5K ﹤0.01% 3483
2020
Q4 		– Sell
-100
Closed -$3K – 4740
2020
Q3 		$3K Buy
+100
New +$3.77K ﹤0.01% 3768
2019
Q4 		– Sell
-600
Closed -$16.5K – 3916
2019
Q3 		$16K Buy
+600
New +$17.1K ﹤0.01% 2318

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cutler Group's ALLO Position: Q4 2023 in Review

Cutler Group sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 1,360 shares — an estimated $4K sold.

Cutler Group first reported a position in ALLO in Q3 2019 and held it in 13 quarters. The position peaked at $73K in Q4 2021. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Cutler Group reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,360 Allogene Therapeutics shares in Q4 2023, an estimated $4K.
  • Cutler Group first reported a position in Allogene Therapeutics in Q3 2019 and held it in 13 quarters.
  • Cutler Group's Allogene Therapeutics position peaked at $73K in Q4 2021.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.